echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Tianshili: "indapamide tablets" passed the consistency evaluation of generic drugs

    Tianshili: "indapamide tablets" passed the consistency evaluation of generic drugs

    • Last Update: 2020-01-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Liaoning Tianshili, a holding subsidiary, recently received the approval document for supplementary application of indapamide tablets (2.5mg) issued by the State Drug Administration, which passed the consistency evaluation of generic drugs, Tianshili announced today (14) The drug submitted an application for conformity assessment to the State Food and Drug Administration on December 11, 2018, and was accepted on December 18, 2018 Indapamide is a kind of sulfonamide diuretic, which has diuretic and calcium antagonistic effects It is a strong and long-acting antihypertensive drug, mainly used in the treatment of essential hypertension Through inquiry, the listed indapamide tablet manufacturers in China mainly include Tianjin Lisheng Pharmaceutical Co., Ltd., Servier (Tianjin) Pharmaceutical Co., Ltd (original research), etc According to the data of PDB drug comprehensive database, the global sales of indapamide tablets in 2018 was $819 million, up 3.80% year on year According to the sales data of pharmaceutical intelligence hospital, from 2016 to 2019, the sales of indapamide tablets in domestic sample hospitals increased year by year, reaching 11.5222 million yuan in 2018, an increase of 18.87% year on year, of which Tianjin Lisheng pharmaceutical accounted for 56.45% Tianshili is the sixth manufacturer in China that has passed the consistency evaluation of this product Chongqing Yaoyou, Guangdong anno pharmaceutical, Sinopharm group, Jushen pharmaceutical and Huiyuan pharmaceutical have been evaluated for drugs of the same specification successively As of the announcement date, Liaoning Tianshili has invested about 7.4807 million yuan in R & D for the consistency evaluation of the drug, Tianshili said Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.